Poly(ADP-ribose) polymerase inhibition improves postischemic myocardial function after cardioplegia-cardiopulmonary bypass

Journal of the American College of Surgeons

Volumn 197, Issue 2, 2003, Pages 270-277

  Khan, Tanveer A ^a   Ruel, Marc ^a   Bianchi, Cesario ^a   Voisine, Pierre ^a   Komjáti, Katalin ^b   Szabo, Csaba ^b   Sellke, Frank W ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b INOTEK CORPORATION   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INO 1001; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCULATION; CARDIOPLEGIA; CARDIOPULMONARY BYPASS; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DRUG EFFECT; DRUG INFUSION; ENZYME ACTIVITY; ENZYME INHIBITION; HEART FUNCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE DP-DT; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; IMMUNOHISTOCHEMISTRY; LEFT ANTERIOR DESCENDING CORONARY ARTERY; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; SWINE; TISSUE SECTION;

EID: 0042166004     PISSN: 10727515     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1072-7515(03)00538-6     Document Type: Article

References (33)

1. Schraufstatter IU, Hinshaw DB, Hyslop PA, et al. Oxidant injury of cells. DNA strand-breaks activate polyadenosine diphosphate-ribose polymerase and lead to depletion of nicotinamide adenine dinucleotide. J Clin Invest 1986;77:1312-1320.
2. Szabo C, Zingarelli B, O'Connor M, et al. DNA strand breakage, activation of poly (ADP-ribose) synthetase, and cellular energy depletion are involved in the cytotoxicity of macrophages and smooth muscle cells exposed to peroxynitrite. Proc Natl Acad Sci USA 1996;93:1753-1758.
3. Gilad E, Zingarelli B, Salzman AL, et al. Protection by inhibition of poly (ADP-ribose) synthetase against oxidant injury in cardiac myoblasts in vitro. J Mol Cell Cardiol 1997;29:2585-2597.
4. Bowes J, McDonald MC, Piper J, et al. Inhibitors of poly (ADP-ribose) synthetase protect rat cardiomyocytes against oxidant stress. Cardiovasc Res 1999;41:126-134.
5. Grupp IL, Jackson TM, Hake P, et al. Protection against hypoxia-reoxygenation in the absence of poly (ADP-ribose) synthetase in isolated working hearts. J Mol Cell Cardiol 1999;31:297-303.
6. Zingarelli B, Cuzzocrea S, Zsengeller Z, et al. Protection against myocardial ischemia and reperfusion injury by 3-aminobenzamide, an inhibitor of poly (ADP-ribose) synthetase. Cardiovasc Res 1997;36:205-215.
7. Wayman N, McDonald MC, Thompson AS, et al. 5-aminoisoquinolinone, a potent inhibitor of poly (adenosine 5′-diphosphate ribose) polymerase, reduces myocardial infarct size. Eur J Pharmacol 2001;430:93-100.
8. Bowes J, Ruetten H, Martorana PA, et al. Reduction of myocardial reperfusion injury by an inhibitor of poly (ADP-ribose) synthetase in the pig. Eur J Pharmacol 1998;359:143-150.
9. Faro R, Toyoda Y, McCully JD, et al. Myocardial protection by PJ34, a novel potent poly (ADP-ribose) synthetase inhibitor. Ann Thorac Surg 2002;73:575-581.
10. Uematsu M, Gaudette GR, Laurikka JO, et al. Adenosine-enhanced ischemic preconditioning decreases infarct in the regional ischemic sheep heart. Ann Thorac Surg 1998;66:382-387.
11. Clermont G, Vergely C, Jazayeri S, et al. Systemic free radical activation is a major event involved in myocardial oxidative stress related to cardiopulmonary bypass. Anesthesiology 2002;96:80-87.
12. Hayashi Y, Sawa Y, Ohtake S, et al. Peroxynitrite formation from human myocardium after ischemia-reperfusion during open heart operation. Ann Thorac Surg 2001;72:571-576.
13. Paparella D, Yau TM, Young E. Cardiopulmonary bypass induced inflammation: pathophysiology and treatment. An update. Eur J Cardiothorac Surg 2002;21:232-244.
14. Ma XL, Weyrich AS, Lefer DJ, et al. Monoclonal antibody to L-selectin attenuates neutrophil accumulation and protects ischemic reperfused cat myocardium. Circulation 1993;88:649-658.
15. Weyrich AS, Ma XY, Lefer DJ, et al. In vivo neutralization of P-selectin protects feline heart and endothelium in myocardial ischemia and reperfusion injury. J Clin Invest 1993;91:2620-2629.
16. Ma XL, Lefer DJ, Lefer AM, et al. Coronary endothelial and cardiac protective effects of a monoclonal antibody to intercellular adhesion molecule-1 in myocardial ischemia and reperfusion. Circulation 1992;86:937-946.
17. Morse DS, Adams D, Magnani B. Platelet and neutrophil activation during cardiac surgical procedures: impact of cardiopulmonary bypass. Ann Thorac Surg 1998;65:691-695.
18. Ilton MK, Langton PE, Taylor ML, et al. Differential expression of neutrophil adhesion molecules during coronary artery surgery with cardiopulmonary bypass. J Thorac Cardiovasc Surg 1999;118:930-937.
19. Szabo C, Virag L, Cuzzocrea S, et al. Protection against peroxynitrite-induced fibroblast injury and arthritis development by inhibition of poly(ADP-ribose) synthase. Proc Natl Acad Sci USA 1998;95:3867-3872.
20. Sawa Y, Taniguchi K, Kadoba K, et al. Leukocyte depletion attenuates reperfusion injury in patients with left ventricular hypertrophy. Circulation 1996;93:1640-1646.
21. Zingarelli B, Salzman AL, Szabo C. Genetic disruption of poly (ADP-ribose) synthetase inhibits the expression of P-selectin and intercellular adhesion molecule-1 in myocardial ischemia/reperfusion injury. Circ Res 1998;83:85-94.
22. Khandoga A, Enders G, Biberthaler P, et al. Poly(ADP-ribose) polymerase triggers the microvascular mechanisms of hepatic ischemia-reperfusion injury. Am J Physiol Gastrointest Liver Physiol 2002;283:G553-G560.
23. Briaud SA, Ding ZM, Michael LH, et al. Leukocyte trafficking and myocardial reperfusion injury in ICAM-I/P-selectin-knockout mice. Am J Physiol Heart Circ Physiol 2001;280: H60-H67.
24. Oliver FJ, Menissier-de Murcia J, Nacci C, et al. Resistance to endotoxic shock as a consequence of defective NF-kappaB activation in poly (ADP-ribose) polymerase-1 deficient mice. EMBO J 1999;18:4446-4454.
25. Garcia Soriano F, Virag L, Jagtap P, et al. Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. Nat Med 2001;7:108-113.
26. Komjáti K, Jagtap PG, Baloglu E, et al. Poly(ADP-ribose) polymerase inhibition in stroke: establishment of the therapeutic window of intervention and delineation of its role in the pathogenesis of white matter damage. FASEB J 2002;16:A599.
27. Szabo G, Bahrie S, Stumpf N, et al. Poly(ADP-ribose) polymerase inhibition reduces reperfusion injury after heart transplantation. Circ Res 2002;90:100-106.
28. Pacher P, Liaudet L, Soriano FG, et al. The role of poly(ADP-ribose) polymerase activation in the development of myocardial and endothelial dysfunction in diabetes. Diabetes 2002;51:514-521.
29. Pacher P, Liaudet L, Mabley J, et al. Pharmacologic inhibition of poly(adenosine diphosphate-ribose) polymerase may represent a novel therapeutic approach in chronic heart failure. J Am Coll Cardiol 2002;40:1006-1016.
30. Goldfarb RD, Marton A, Szabo E, et al. Protective effect of a novel, potent inhibitor of poly(adenosine 5′-diphosphate-ribose) synthetase in a porcine model of severe bacterial sepsis. Crit Care Med 2002;30:974-980.
31. Pacher P, Liaudet L, Bai P, et al. Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure. J Pharmacol Exp Ther 2002;300:862-867.
32. Baumgartner WA, Walinsky PL, Salazar JD, et al. Assessing the impact of cerebral injury after cardiac surgery: will determining the mechanism reduce this injury? Ann Thorac Surg 1999;67:1871-1873; discussion 1891-1894.
33. Virag L, Szabo C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev 2002;54:375-429.